10-Q quarterly report · filed Oct 29, 2026

Bausch Health Companies Inc (BHC) Q3 2026 10-Q Quarterly Report

Short answer

Bausch Health Companies Inc (BHC) filed its Q3 2026 10-Q quarterly report on Oct 29, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $2.9B (up 9.7% year over year) with net income of $436M.

Q3 2026 key financials · XBRL

Revenue
$2.9B
+9.7% YoY · +3.1% QoQ
Net income
$436M
+143.6% YoY · +69.0% QoQ
Operating margin
33.4%
EPS (diluted)
$1.17
+143.8% YoY · +67.1% QoQ

Source: XBRL data from the Bausch Health Companies Inc (BHC) Q3 2026 10-Q on SEC EDGAR. USD.

Bausch Health Companies Inc Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Revenue $2,941M, up 10% YoY from $2,681M, driven by pricing gains and acquisitions
  • Operating margin 33.4% vs 23.1% YoY, with operating income $983M vs $619M
  • Best segment: Salix revenue $831M, up 16%; worst growth: International revenue $299M, up 5%
  • Nine-month operating cash flow $1,714M vs $905M; ending cash $2,488M vs $1,340M
  • Near-term headwinds: Xifaxan negotiated pricing effective 2027, generic entry expected 2028, and ongoing tariff and regulatory risks

Risk Factors

  • New governance risk: Thomas Appio became Bausch + Lomb interim CEO October 12, 2026
  • Management bandwidth risk: Appio’s overlapping CEO roles may create competing demands
  • Conflict-of-interest risk: Appio also became Bausch + Lomb chairman in August 2026
  • Reputational risk: dual-company responsibilities may create actual or perceived conflicts

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.